Simulations Plus – Consensus Indicates Potential 21.6% Upside
Simulations Plus found using ticker (SLP) have now 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 75 and 54 and has a mean target at 60. Given that the stocks previous close was at 49.33 this indicates there is a potential upside of 21.6%. The 50 day MA is 46.44 and the 200 day MA is 45.51. The company has a market cap of $1,008m. Find out more information at: https:||www.simulations-plus.com [stock_market_widget type="chart" template="basic" color="green" assets="SLP" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $1,225m based on the market concensus. Simulations Plus develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals
Simulations Plus – Consensus Indicates Potential 21.6% Upside
Simulations Plus found using ticker (SLP) have now 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 75 and 54 and has a mean target at 60. Given that the stocks previous close was at 49.33 this indicates there is a potential upside of 21.6%. The 50 day MA is 46.44 and the 200 day MA is 45.51. The company has a market cap of $1,008m. Find out more information at: https:||www.simulations-plus.com [stock_market_widget type="chart" template="basic" color="green" assets="SLP" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $1,225m based on the market concensus. Simulations Plus develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals